en
Scientific article
English

Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect

Published inImmunology, vol. 143, no. 3, p. 428-437
Publication date2014
Abstract

Despite the efficacy of current immune-chemotherapy for treatment of B-cell non-Hodgkin lymphoma, a substantial proportion of patients relapse, highlighting the need for new therapeutic modalities. The use of live microorganisms to develop anti-tumoural therapies has evolved since Coley's toxin and is now receiving renewed attention. Salmonella Typhimurium has been shown to be highly effective as an anti-tumour agent in many solid cancer models, but it has not been used in haemato-oncology. Here, we report that intra-tumoural administration of LVR01 (attenuated S. Typhimurium strain with safety profile) elicits local and systemic anti-tumour immunity, resulting in extended survival in a lymphoma model. LVR01 induces intra-tumoural recruitment of neutrophils and activated CD8(+) T cells, as well as increasing the natural killer cell activation status. Furthermore, a systemic specific anti-tumour response with a clear T helper type 1 profile was observed. This approach is an alternative therapeutic strategy for lymphoma patients that could be easily moved into clinical trials.

Keywords
  • Bacteria
  • Tumour immunology
  • Vaccination
Affiliation Not a UNIGE publication
Citation (ISO format)
GRILLE, Sofía et al. Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. In: Immunology, 2014, vol. 143, n° 3, p. 428–437. doi: 10.1111/imm.12320
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0019-2805
368views
0downloads

Technical informations

Creation02/04/2018 4:31:00 PM
First validation02/04/2018 4:31:00 PM
Update time03/15/2023 7:51:48 AM
Status update03/15/2023 7:51:47 AM
Last indexation01/17/2024 2:16:02 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack